Cargando...
Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
Brentuximab vedotin is a monoclonal antibody that targets the CD30 antigen. It is indicated for the treatment of Hodgkin lymphoma. Hypersensitivity reactions have occurred during infusions of brentuximab vedotin, ranging from mild to severe. We report a case of a 46-year-old male with stage IV nodul...
Guardado en:
| Publicado en: | Cureus |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Cureus
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6141060/ https://ncbi.nlm.nih.gov/pubmed/30237942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2981 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|